Cambridge Theranostics Ltd, Babraham Research Campus, Babraham, Cambridge CB24AT, United Kingdom.
Int J Med Sci. 2010 Jun 10;7(4):181-90. doi: 10.7150/ijms.7.181.
Limited body of evidence suggests that lipopolysaccharide of C. pneumoniae as well as C. pneumoniae-specific immune complexes can be detected and isolated from human serum. The aim of this study was to investigate the presence of viable elementary bodies of C.pneumoniae in serum samples of patients with acute coronary syndrome and healthy volunteers.
Serum specimens from 26 healthy volunteers and 56 patients with acute coronary syndrome were examined subsequently by serological (C.pneumoniae-specific IgA and IgG), PCR-based and bacteriological methods. Conventional, nested and TaqMan PCR were used to detect C.pneumoniae genetic markers (ompA and 16S rRNA) in DNA from serum specimens extracted with different methods. An alternative protocol which included culturing high-speed serum sediments in HL cells and further C.pneumoniae growth evaluation with immunofluorescence analysis and TaqMan PCR was established. Pellet fraction of PCR-positive serum specimens was also examined by immunoelectron microscopy.
Best efficiency of final PCR product recovery from serum specimens has been shown with specific C. pneumoniae primers using phenol-chloroform DNA extraction protocol. TaqMan PCR analysis revealed that human serum of patients with acute coronary syndrome may contain genetic markers of C. pneumoniae with bacterial load range from 200 to 2000 copies/ml serum. However, reliability and reproducibility of TaqMan PCR were poor for serum specimens with low bacterial copy number (<200 /ml). Combination of bacteriological, immunofluorescence and PCR- based protocols applied for the evaluating HL cells infected with serum sediments revealed that 21.0 % of the patients with acute coronary syndrome have viable forms C.pneumoniae in serum. The detection rate of C.pneumoniae in healthy volunteers was much lower (7.7%). Immunological profile of the patients did not match accurately C.pneumoniae detection rate in serum specimens. Elementary bodies of C.pneumoniae with typical ultrastructural characteristics were also identified in serum sediments using immunoelectron microscopy.
Viable forms C. pneumoniae with typical electron microscopic structure can be identified and isolated from serum specimens of the patients with acute coronary syndrome and some healthy volunteers. Increased detection rate of C. pneumoniae in serum among the patients with an acute coronary syndrome may contribute towards enhanced pro-inflammatory status in cardiovascular patients and development of secondary complications of atherosclerosis.
有限的证据表明,肺炎衣原体的脂多糖以及肺炎衣原体特异性免疫复合物可以从人类血清中检测和分离出来。本研究的目的是调查急性冠状动脉综合征患者和健康志愿者血清样本中是否存在存活的肺炎衣原体原体。
随后,通过血清学(肺炎衣原体特异性 IgA 和 IgG)、基于 PCR 和细菌学方法检查了 26 名健康志愿者和 56 名急性冠状动脉综合征患者的血清标本。使用不同方法从血清标本中提取 DNA 后,采用常规、巢式和 TaqMan PCR 检测肺炎衣原体的遗传标记(ompA 和 16S rRNA)。建立了一种替代方案,包括在 HL 细胞中培养高速血清沉淀物,并通过免疫荧光分析和 TaqMan PCR 进一步评估肺炎衣原体的生长。还通过免疫电子显微镜检查了 PCR 阳性血清标本的沉淀部分。
使用特定的肺炎衣原体引物和酚氯仿 DNA 提取方案从血清标本中获得最终 PCR 产物的效率最佳。TaqMan PCR 分析显示,急性冠状动脉综合征患者的人血清可能含有肺炎衣原体的遗传标记,其细菌负荷范围为 200 至 2000 拷贝/ml 血清。然而,对于细菌拷贝数低(<200/ml)的血清标本,TaqMan PCR 的可靠性和可重复性较差。用于评估感染 HL 细胞的血清沉淀物的细菌学、免疫荧光和基于 PCR 的方案组合表明,21.0%的急性冠状动脉综合征患者的血清中有存活形式的肺炎衣原体。健康志愿者的肺炎衣原体检测率要低得多(7.7%)。患者的免疫学特征与血清标本中肺炎衣原体的检测率并不完全匹配。使用免疫电子显微镜也在血清沉淀物中鉴定出具有典型超微结构特征的肺炎衣原体原体。
从急性冠状动脉综合征患者和一些健康志愿者的血清标本中可以鉴定和分离出具有典型电子显微镜结构的存活形式的肺炎衣原体。急性冠状动脉综合征患者血清中肺炎衣原体的检测率增加可能导致心血管患者的促炎状态增强,并导致动脉粥样硬化的继发性并发症发展。